ABL Bio Showcases Bispecific Antibody Platform "Grabody-T" at ADC Summit

Presentation of Antitumor Efficacy and Safety of 4-1BB-Based Bispecific Antibody Platform
Zibastomig Undergoing Phase 2 Trials... Largistomig Expands to Combination Therapy

ABL Bio announced on June 11 that it presented the current status of development and key pipeline achievements for its 4-1BB-based bispecific antibody platform, Grabody-T, at the "World Bispecific & T Cell Engager Summit Korea 2026," held in Magok, Seoul from June 9 to 11.

ABL Bio company logo image. ABL Bio

On June 10, ABL Bio gave a presentation on the theme of "Optimization of T Cell Engagers from Preclinical Research to Clinical Trials," introducing the antitumor efficacy and safety data of Grabody-T-based candidates.

Grabody-T is a bispecific antibody platform that simultaneously targets 4-1BB, a T cell activation receptor, and tumor-associated antigens (TAA). It is designed to activate T cells only within the tumor microenvironment where cancer cells are present, thereby reducing the liver toxicity issues raised during the development of 4-1BB targeted therapies.

Major pipeline candidates include zibastomig (ABL111), a gastric cancer therapeutic candidate, and largistomig (ABL503), a solid tumor therapeutic candidate. Zibastomig is undergoing a Phase 2 clinical trial as a first-line treatment for gastric cancer in combination with chemotherapy and PD-1 inhibitors. Largistomig recently expanded its development scope to combination therapy with PD-1 inhibitors, following Phase 1 clinical trials as a monotherapy.

ABL Bio is currently conducting clinical development of 10 bispecific antibody pipelines in the United States, China, Australia, and Korea. The biliary tract cancer therapeutic candidate, tolvesimig (ABL001), has received both Fast Track and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). Zibastomig is being co-developed with Novabridge, and additional Phase 1b clinical data are scheduled to be released at a global conference in the second half of this year.

ABL Bio CEO Lee Sanghoon stated, "Interest is growing as the safety and efficacy of 4-1BB-based bispecific antibodies are being confirmed in clinical trials," adding, "We plan to continue advancing the clinical development and global commercialization of our key pipeline candidates."

This content was produced with the assistance of AI translation services.